Immunotherapy (IT) with ch14.18/CHO for high-risk neuroblastoma: First results from the randomised HR-NBL1/SIOPEN trial. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results